Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB-201 in Moderate to Severe Plaque Psoriasis (Phase 2)
2012-002763-10Phase 2Completed
- Sponsor
- VBL Therapeutics
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing VB-201 (dose-ranging) with Placebo (2 arms). Primary endpoint: Stage 1 Primary Efficacy Endpoints. Started Oct 2012; status: completed.
02
Drugs
VB-201
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2012-002763-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002763-10.